Lipid Metabolism Practice Questions

Q: In patients with Retinitis pigmentosa, which of the following substances is known to have decreased levels?

Docosahexaenoic acid (DHA). ***Docosahexaenoic acid (DHA)*** - **Docosahexaenoic acid (DHA)** is a crucial **omega-3 fatty acid** abundantly found in the **photoreceptor cell membranes**, particularly in the retina. - Reduced levels of DHA are frequently observed in patients with **retinitis pigmentosa**, suggesting its role in disease pathogenesis and retinal health. *Arachidonic acid* - **Arachidonic acid** is an **omega-6 fatty acid** and a precursor to many signaling molecules, but its levels are **not typically decreased** in retinitis pigmentosa. - It plays a **pro-inflammatory role** and is involved in various physiological processes, distinct from the primary metabolic defects in retinitis pigmentosa. *Linoleic acid* - **Linoleic acid** is an essential **omega-6 fatty acid** and a precursor to arachidonic acid, but its deficiencies are not characteristic of retinitis pigmentosa. - It is crucial for **skin barrier function** and overall health, but its metabolic pathways are distinct from those primarily affected in retinal degenerations. *Thromboxane* - **Thromboxane** is a **lipid mediator** primarily involved in **platelet aggregation** and vasoconstriction. - It is not directly associated with the metabolic pathways or structural integrity of the retina, and its levels are not typically altered in retinitis pigmentosa.

Q: X-linked adrenoleukodystrophy is a type of:

Fatty acid disorder. ***Fatty acid disorder*** - **X-linked adrenoleukodystrophy (X-ALD)** is characterized by impaired peroxisomal beta-oxidation of **very long-chain fatty acids (VLCFAs)**, leading to their accumulation. - This accumulation primarily affects the **adrenal glands** and **nervous system**, causing progressive demyelination and adrenal insufficiency. *Lysosomal storage disorder* - **Lysosomal storage disorders** involve defects in lysosomal enzymes, leading to the accumulation of specific substrates within lysosomes. - While X-ALD involves fat metabolism, the affected organelles are **peroxisomes**, not lysosomes. *Mucopolysaccharidoses* - **Mucopolysaccharidoses (MPS)** are a group of lysosomal storage disorders characterized by the defective breakdown of **glycosaminoglycans (GAGs)**, also known as mucopolysaccharides. - These disorders present with skeletal abnormalities, intellectual disability, and organomegaly, which are distinct from the primary pathology of X-ALD. *Glycogen defect disorder* - **Glycogen defect disorders** (or glycogen storage diseases) result from mutations in enzymes involved in **glycogen synthesis or breakdown**. - These conditions primarily affect carbohydrate metabolism and can lead to symptoms like hypoglycemia, muscle weakness, and hepatomegaly, distinct from the fatty acid metabolism defect in X-ALD.

Q: Which of the following statements about the properties of VLDL and LDL is true?

LDL is formed from VLDL.. ***LDL is formed from VLDL.*** - **Very low-density lipoprotein (VLDL)** is secreted by the liver and transports **triglycerides** to peripheral tissues. As most of the triglycerides are removed by **lipoprotein lipase**, VLDL is converted into **intermediate-density lipoprotein (IDL)** and then further to **low-density lipoprotein (LDL)**. - This conversion primarily occurs in the bloodstream as VLDL loses its triglyceride content. - This statement is **unambiguously true** and represents the established metabolic pathway. *VLDL remnants are primarily taken up by the liver.* - While this statement has some truth, **VLDL remnants (IDL)** have **two major fates**: approximately **50% are taken up by the liver** via apoE-mediated endocytosis through the **LDL receptor** and **LRP**, while the remaining **50% are converted to LDL** by hepatic lipase. - The term "primarily" (meaning mostly or mainly) is thus **not entirely accurate** since both pathways are equally significant. - In contrast, **chylomicron remnants** are almost exclusively (>90%) taken up by the liver, making this statement more applicable to them. *LDL is formed in the liver.* - The liver primarily produces and secretes **VLDL**, not LDL directly. - LDL is a product of the **catabolism** of VLDL in the circulation, not formed de novo in the liver. *In electrophoresis, VLDL migrates less cathodal than LDL.* - In standard **agarose gel electrophoresis**, **VLDL** migrates in the **pre-beta** region, which is **more cathodal** (less anodic) than **LDL** which migrates in the **beta** region. - This means VLDL is more cathodal than LDL, making this statement **incorrect** (it states the opposite).

Q: Which of the following is a transfatty acid?

Elaidic acid. ***Elaidic acid*** - **Elaidic acid** is a common **trans-fatty acid** found in partially hydrogenated vegetable oils. - Its chemical structure includes a **trans double bond**, which gives it properties distinct from cis-fatty acids. *Oleic acid* - **Oleic acid** is a **monounsaturated fatty acid** commonly found in olive oil and other plant fats. - It has a **cis double bond**, which causes a bend in its molecular structure. *Stearic acid* - **Stearic acid** is a **saturated fatty acid** with no double bonds in its carbon chain. - It is found in animal fats and some plant oils, and its straight chain allows for tight packing. *Arachidonic acid* - **Arachidonic acid** is a **polyunsaturated omega-6 fatty acid** with multiple cis double bonds. - It is involved in inflammation and is a precursor to eicosanoids.

Q: Which of the following is not an essential fatty acid?

Palmitic acid. ***Palmitic acid*** - **Palmitic acid** is a **saturated fatty acid** that can be synthesized by the human body and is therefore not considered essential. - It is one of the most common fatty acids in animals and plants and is a major component of membrane lipids. *Linoleic acid* - **Linoleic acid** (an **omega-6 fatty acid**) is an essential fatty acid because the human body cannot synthesize it and it must be obtained from the diet. - It serves as a precursor for other fatty acids, including **arachidonic acid**. *Linolenic acid* - **Linolenic acid** (an **omega-3 fatty acid**) is an essential fatty acid that the human body cannot produce. - It is critical for cell membrane structure and as a precursor for other important fatty acids like **EPA** and **DHA**. *Arachidonic acid* - While important for various biological processes, **arachidonic acid** can be synthesized in the body from the essential fatty acid **linoleic acid**. - Therefore, it is considered conditionally essential, as its essentiality depends on adequate intake of its precursor.

Q: All are true about beta oxidation of fatty acids except which of the following?

Carnitine Acyl transferase I is stimulated by malonyl CoA. ***Carnitine Acyl transferase I is stimulated by malonyl CoA*** - Malonyl CoA is a key intermediate in **fatty acid synthesis** and acts as an **inhibitor** of carnitine acyltransferase I (CAT1), not a stimulator. - This inhibition ensures that when fatty acid synthesis is active, fatty acid oxidation is suppressed, preventing a futile cycle. *Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation* - **Carnitine palmitoyltransferase 1 (CPT1)**, also known as carnitine acyltransferase I, is indeed the **rate-limiting step** for long-chain fatty acid entry into the mitochondrial matrix for beta-oxidation. - This enzyme controls the transport of fatty acyl-CoA into the mitochondria, which is essential for its subsequent breakdown. *Carnitine acyl transferase I is inhibited by malonyl CoA.* - **Malonyl CoA**, a precursor in fatty acid synthesis, serves as an allosteric inhibitor of **CAT1**. - This mechanism ensures that when the cell is actively synthesizing fatty acids, it simultaneously prevents their breakdown, helping to regulate overall energy metabolism. *Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels* - A defect in **CAT1** means fatty acids cannot be efficiently transported into the mitochondria to be converted into acylcarnitine for transport. - This leads to an accumulation of **free fatty acids** in the cytoplasm and a **decrease in acylcarnitine levels** in the blood and tissues, which can be used diagnostically.

Q: What is the parameter that is used to assess lipid peroxidation?

Malondialdehyde. ***Malondialdehyde*** - **Malondialdehyde (MDA)** is a well-established and commonly used biomarker to quantify the level of **lipid peroxidation** in biological systems. - It is a **reactive aldehyde** formed during the decomposition of polyunsaturated fatty acids, particularly through **free radical attack**. *CRP* - **CRP (C-reactive protein)** is a general **inflammatory marker** that indicates acute phase responses in the body. - While inflammation can be associated with oxidative stress, CRP itself does not directly measure **lipid peroxidation**. *hsCRP* - **hsCRP (high-sensitivity C-reactive protein)** is a more sensitive measure of **inflammation**, often used to assess cardiovascular risk. - Like standard CRP, it is an **indicator of systemic inflammation** and not a direct measure of **lipid peroxidation**. *Carboxymethyl lysine* - **Carboxymethyl lysine (CML)** is an **advanced glycation end-product (AGE)**, formed by non-enzymatic reactions between sugars and proteins or lipids. - It is a marker of **glycation and oxidative stress**, but it does not specifically measure **lipid peroxidation**.

Q: Which of the following is NOT a product derived from HMG CoA?

Bile pigments. ***Bile pigments*** - **Bile pigments** (like bilirubin and biliverdin) are derived from the degradation of **heme** from red blood cells and are completely unrelated to the HMG-CoA pathway. - Bile pigments are NOT products of cholesterol or isoprenoid metabolism. *Ubiquinone* - **Ubiquinone** (Coenzyme Q10) is synthesized via the **mevalonate pathway**, which begins with HMG-CoA being converted to mevalonate by **HMG-CoA reductase**. - The mevalonate pathway produces **isopentenyl pyrophosphate (IPP)**, which is used to synthesize ubiquinone, making it a downstream product of HMG-CoA. *Dolichol* - **Dolichol** is a long-chain isoprenoid alcohol essential for **N-glycosylation** of proteins in the endoplasmic reticulum. - Like ubiquinone, dolichol is synthesized from **isoprenoid units** derived from the mevalonate pathway, making it a product of HMG-CoA metabolism. *Ketone bodies* - **Ketone bodies** (acetoacetate and β-hydroxybutyrate) are directly synthesized from **HMG-CoA** in the mitochondria during fasting or low carbohydrate states. - The enzyme **HMG-CoA lyase** cleaves HMG-CoA to produce acetoacetate, which is then converted to other ketone bodies.

Question 1

In patients with Retinitis pigmentosa, which of the following substances is known to have decreased levels?

Accepted Answer

Docosahexaenoic acid (DHA)

Answer

Thromboxane

Answer

Arachidonic acid

Answer

Linoleic acid

Question 2

X-linked adrenoleukodystrophy is a type of:

Accepted Answer

Fatty acid disorder

Answer

Lysosomal storage disorder

Answer

Glycogen defect disorder

Answer

Mucopolysaccharidoses

Question 3

Which of the following statements about the properties of VLDL and LDL is true?

Accepted Answer

LDL is formed from VLDL.

Answer

VLDL remnants are primarily taken up by the liver.

Answer

LDL is formed in the liver.

Answer

In electrophoresis, VLDL migrates less cathodal than LDL.

Question 4

Which of the following is a transfatty acid?

Accepted Answer

Elaidic acid

Answer

Oleic acid

Answer

Stearic acid

Answer

Arachidonic acid

Question 5

Which of the following is not an essential fatty acid?

Accepted Answer

Palmitic acid

Answer

Linolenic acid

Answer

Linoleic acid

Answer

Arachidonic acid

Question 6

Which of the following statements about reverse cholesterol transport is false?

Accepted Answer

Lecithin Cholesterol Acyl Transferase helps in the conversion of Spheroidal HDL to Discoidal HDL.

Answer

Transport of cholesterol from extrahepatic tissues to liver.

Answer

Cholesterol Ester Transfer Protein reduces HDL levels.

Answer

ATP Binding Cassette Transporter protein is involved in the conversion of HDL3 to HDL2.

Question 7

All are true about beta oxidation of fatty acids except which of the following?

Accepted Answer

Carnitine Acyl transferase I is stimulated by malonyl CoA

Answer

Carnitine Acyl transferase I defect causes a decrease in acylcarnitine levels

Answer

Carnitine acyl transferase I is the rate limiting enzyme of fatty acid oxidation

Answer

Carnitine acyl transferase I is inhibited by malonyl CoA

Question 8

Which of the following statements about beta oxidation of fatty acids is correct?

Accepted Answer

Fatty acid oxidation defects can lead to hypoglycemia.

Answer

Ketone bodies are formed by complete oxidation of fatty acids during starvation.

Answer

Odd chain fatty acid oxidation provides only propionyl CoA.

Answer

Stearic acid on oxidation provides 120 ATPs.

Question 9

What is the parameter that is used to assess lipid peroxidation?

Accepted Answer

Malondialdehyde

Answer

CRP

Answer

hsCRP

Answer

Carboxymethyl lysine

Question 10

Which of the following is NOT a product derived from HMG CoA?

Accepted Answer

Bile pigments

Answer

Dolichol

Answer

Ketone bodies

Answer

Ubiquinone

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?